August 2, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Re: | ROSETTA GENOMICS LTD. |
Registration Statement on Form F-1 (Registration No. 333-217765) |
Concurrence in Acceleration Request |
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Rosetta Genomics Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on August 3, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours, | ||
H.C. Wainwright & Co., LLC | ||
By: | /s/ Mark W. Viklund | |
Name: Mark W. Viklund Title: Chief Executive Officer |